Application and expectation of patient-derived tumor xenograft models in the treatment of pancreatic cancer
10.3760/cma.j.cn115396-20210527-00193
- VernacularTitle:人源性肿瘤组织异种移植模型在胰腺癌综合治疗中的应用及展望
- Author:
Jiyao SHENG
1
;
Hanjiao QIN
;
Xuewen ZHANG
Author Information
1. 吉林大学第二医院肝胆胰外科 吉林省肝胆胰疾病转化医学工程实验室，长春 130041
- Keywords:
Pancreatic neoplasms;
Xenograft model antitumor assays;
Antineoplastic combined chemotherapy protocols;
Molecular targeted therapy;
Precision medicine
- From:
International Journal of Surgery
2021;48(6):366-370
- CountryChina
- Language:Chinese
-
Abstract:
Pancreatic cancer has a poor prognosis, systemic comprehensive therapy including chemotherapeutic and molecular targeted therapy is the key to improve the postoperative prognosis of pancreatic cancer, as well as to prolong the survival time of advanced pancreatic cancer. However, due to the drug resistance and heterogeneity of pancreatic cancer cells, systemic comprehensive treatment still does not reach the ideal effect, and personalized therapy will be an important approach to solve this problem. The personalized therapy for pancreatic cancer will become possible with the application of patient-derived tumor xenograft (PDX) models. Here, this article will review the progress of the application of PDX models in comprehensive therapy of pancreatic cancer based on reviewing the methods of establishing pancreatic cancer PDX models, aiming to provide new ideas for personalized therapy of pancreatic cancer.
